Black Diamond Hits 86% CNS-ORR, FDA Backs Pivotal Path

Black Diamond Therapeutics (Nasdaq: BDTX) announced on 10 November 2026 that updated Phase 2 results for its investigational drug silevertinib showed an 86% CNS objective response rate (CNS-ORR) in 16 frontline EGFR non-classical mutation (NCM) NSCLC patients with untreated brain metastases, alongside a 15.0-month median progression-free survival (mPFS) in the 43-patient intention-to-treat population. The company also disclosed feedback from its 1 October 2026 End-of-Phase 2 meeting with the FDA, which it said supports a path to potential accelerated and full approval, and reported $102.0 million in cash, cash equivalents and investments as of 30 September 2026.

Context — why this matters now

The updated readout matters because Black Diamond is a clinical-stage company with no approved products and no license revenue in the quarter. The report shows license revenue of zero for the three and nine months ended 30 September 2026, against $70.0 million in the prior-year nine-month period. That comparison frames why the silevertinib data and the FDA feedback carry the company's near-term valuation weight.

The FDA meeting, held 1 October 2026, gave the company a defined registration structure rather than an open-ended dialogue. The company said it intends to pursue a Phase 3 program covering all treatment-naïve patients with locally advanced or metastatic NSCLC whose tumors harbor an oncogenic EGFR mutation other than a classical mutation (ex19del, L858R) or an exon 20 insertion. That is the population the company describes as roughly 25% of frontline EGFR-mutant patients.

The catalyst chain runs from the October data cutoff to the planned Phase 3 start. The company needs safety data from a sufficient number of patients treated at 150 mg once daily in the ongoing Cohort 4 before the FDA will allow the Phase 3 trial to open. Cohort 4 is enrolling, with the first patient dosed in the third quarter of 2026.

The macro backdrop is secondary here. The report does not tie the readout to rate or index levels, and the company's $102.0 million cash position, down from $128.7 million at 31 December 2025, is the relevant balance-sheet fact for a pre-revenue biotech.

Data — what the numbers show

In the 43-patient ITT group, the company reported 60% ORR by RECIST 1.1, 93% disease control rate and 15.0-month mPFS with a 95% confidence interval of 11.0 to 23.5 months. Eighteen patients remained on therapy, with the longest at 26.2 months. The company said no new safety signals were observed.

Population	n	Key result
ITT	43	60% ORR, 15.0-month mPFS
Untreated brain metastases	16 (7 RANO-BM evaluable)	86% CNS-ORR, 12.2-month systemic mPFS
No brain metastases	24	23.5-month mPFS

The brain-metastasis subgroup shows the split the company is building its regulatory case on: 86% CNS-ORR in the seven RANO-BM evaluable patients, against 12.2-month systemic mPFS by RECIST 1.1 with a confidence interval of 8.1 months to not estimable. In the 24 patients without baseline brain metastases, mPFS was 23.5 months, with a confidence interval of 11.0 months to not estimable, and the company said no patients progressed in the brain.

Third-quarter financials show R&D expenses of $6.97 million versus $7.44 million a year earlier, G&A of $5.15 million versus $3.54 million, and a net loss of $10.01 million versus $8.50 million. Net cash used in operations was $8.3 million for the quarter.

Analysis — what it means for markets / sectors / tickers

The reported CNS-ORR is the number the regulatory strategy rests on, because the FDA gave feedback on a potential accelerated approval based on CNS-ORR per RANO-BM by blinded independent central review. That endpoint, not systemic response, is the near-term gate. The company also said the FDA indicated systemic ORR and overall survival will need to be evaluated to show systemic ORR similarity to, and no evidence of an OS detriment compared to, the control arm.

The planned Phase 3 randomizes 300 patients with untreated brain metastases 1:1 to silevertinib 150 mg once daily or physician's choice of osimertinib or afatinib, with an additional 80-patient single-arm cohort without brain metastases and a 20-patient leptomeningeal cohort. That design puts silevertinib directly against the incumbent EGFR TKIs in the same trial, which is a higher bar than a single-arm readout.

The limitation is structural. The Phase 2 data come from a single-arm trial, and the report itself notes no head-to-head trials have been conducted and that cross-trial comparisons are limited by differences in trial design, patient population, endpoints and dosing. The company's claim that mPFS is double that of currently available EGFR TKIs is therefore a cross-trial comparison, not a randomized result.

Positioning depends on the Cohort 4 safety readout. Until enough 150 mg patients are treated and submitted, the Phase 3 cannot open, so the timeline carries execution risk rather than regulatory risk at this stage.

Outlook — what to watch next

The company said it plans to initiate the global Phase 3 registrational trial in the second quarter of 2027, with preliminary data anticipated in 2028. Before that, safety data from Cohort 4 at 150 mg once daily must be submitted to the FDA.

In the GBM program, the randomized portion of the Phase 2 trial in newly diagnosed EGFRvIII+ glioblastoma is enrolling at 150 mg once daily, with the first patient dosed in the fourth quarter of 2026 and interim PFS data expected in the first half of 2028. The dose was selected after six patients received 150 mg with temozolomide in a safety run-in with no dose-limiting toxicities observed.

On funding, the company said its cash, cash equivalents and investments are sufficient to fund anticipated operating expenses and capital expenditure requirements into the second half of 2028. No price levels are cited in the report.

Frequently Asked Questions

What does the 86% CNS-ORR mean for Black Diamond Therapeutics?

It is the response rate the company is using to pursue potential accelerated approval. The FDA gave feedback on an accelerated approval based on CNS-ORR per RANO-BM by blinded independent central review. The figure comes from seven RANO-BM evaluable patients out of 16 with untreated brain metastases, so the evaluable sample is small and the Phase 3 is designed to confirm it in 300 randomized patients.

What happens next for BDTX before the Phase 3 trial starts?

The company must submit safety data from a sufficient number of patients treated at 150 mg once daily in Cohort 4, which is enrolling frontline EGFR-NCM patients. The FDA requires that submission before the Phase 3 trial can open. The company targets a second-quarter 2027 initiation, with preliminary data anticipated in 2028.

Why did Black Diamond's net loss widen year over year?

Net loss was $10.01 million in the third quarter of 2026 versus $8.50 million a year earlier. R&D fell to $6.97 million from $7.44 million, but G&A rose to $5.15 million from $3.54 million, which the company attributed to higher IP-related costs and non-income tax expense. The wider loss reflects that G&A increase outpacing the R&D decline.

Bottom Line

Black Diamond's silevertinib brain-metastasis data and FDA feedback now carry a defined, but unopened, Phase 3 path.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.